Figure 5: Triple-acting fusions can reduce S. aureus induced mastitis in a mouse model.
From: Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus
(A) Specific activity of PGH fusion constructs in vitro. Turbidity reduction assay with S. aureus Newbould 305 resuspended in lysis buffer to an OD600nm of 1.0 and treated with 1 μM final concentrations of each PGH. The maximum specific activity for three experiments is represented as an average with SEM error bars. Single asterisks indicate significant difference from buffer control (p < 0.05); double asterisks indicate significant difference from parental enzyme (p < 0.05). (B) Bacterial burden in mice with mastitis treated with recombinant PGHs. CFUs from infected murine mammary glands following a single treatment with 50 μl of 25 μM PGH (1.25 nmol). Each data point represents the average of duplicate bacterial platings. The horizontal bars represent the average CFU/mg for each group. (C) TNFα response in mice with mastitis that were treated with PGHs. Data represent a minimum of 7 measurements in duplicate. Log TNFα was used for statistical analysis. Single asterisk indicates a significant difference from buffer control (p < 0.05); double asterisk indicates significant difference from parental enzyme (p < 0.05).
